IN2013MN01519A - - Google Patents
Download PDFInfo
- Publication number
- IN2013MN01519A IN2013MN01519A IN1519MUN2013A IN2013MN01519A IN 2013MN01519 A IN2013MN01519 A IN 2013MN01519A IN 1519MUN2013 A IN1519MUN2013 A IN 1519MUN2013A IN 2013MN01519 A IN2013MN01519 A IN 2013MN01519A
- Authority
- IN
- India
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- diaminopyrimidine derivative
- delayed
- gastroparesis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20110016981 | 2011-02-25 | ||
| PCT/KR2012/001423 WO2012115478A2 (en) | 2011-02-25 | 2012-02-24 | Diaminopyrimidine derivatives and processes for the preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2013MN01519A true IN2013MN01519A (es) | 2015-06-12 |
Family
ID=46721361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1519MUN2013 IN2013MN01519A (es) | 2011-02-25 | 2012-02-24 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9850227B2 (es) |
| EP (2) | EP2678331B1 (es) |
| JP (2) | JP5980236B2 (es) |
| KR (2) | KR101671348B1 (es) |
| CN (2) | CN103402997B (es) |
| AU (2) | AU2012221927B2 (es) |
| BR (2) | BR112013020641B1 (es) |
| CA (2) | CA2827072C (es) |
| DK (1) | DK2678332T3 (es) |
| ES (2) | ES2587304T3 (es) |
| HK (2) | HK1188215A1 (es) |
| HU (1) | HUE029988T2 (es) |
| IN (1) | IN2013MN01519A (es) |
| MX (2) | MX336155B (es) |
| PL (2) | PL2678331T3 (es) |
| PT (1) | PT2678332T (es) |
| RU (1) | RU2587493C2 (es) |
| WO (2) | WO2012115480A2 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012221927B2 (en) * | 2011-02-25 | 2016-04-28 | Yuhan Corporation | Diaminopyrimidine derivatives and processes for the preparation thereof |
| CA2892045C (en) | 2012-11-21 | 2022-05-31 | Ptc Therapeutics, Inc. | Substituted reverse pyrimidine bmi-1 inhibitors |
| KR101657616B1 (ko) * | 2013-05-24 | 2016-09-19 | 주식회사유한양행 | 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법 |
| NZ748260A (en) * | 2013-08-30 | 2020-01-31 | Ptc Therapeutics Inc | Substituted pyrimidine bmi-1 inhibitors |
| US10584115B2 (en) | 2013-11-21 | 2020-03-10 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine BMI-1 inhibitors |
| CN104003944B (zh) * | 2014-05-29 | 2016-08-24 | 西北师范大学 | 一种嘧菌胺的制备方法 |
| MX2017003181A (es) * | 2014-10-13 | 2017-07-20 | Yuhan Corp | Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidermico. |
| US10300155B2 (en) | 2015-12-31 | 2019-05-28 | Washington University | Alpha-synuclein ligands |
| CN105646321A (zh) * | 2016-01-07 | 2016-06-08 | 中国药科大学 | (s)-3-羟基吡咯烷盐酸盐的制备方法 |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| KR102441327B1 (ko) | 2018-05-18 | 2022-09-07 | 주식회사유한양행 | 다이아미노피리미딘 유도체 또는 이의 산부가염의 신규의 제조방법 |
| CN110317176A (zh) * | 2019-07-04 | 2019-10-11 | 沈阳药科大学 | 2-氨基嘧啶类化合物及其用途 |
| KR20220006776A (ko) * | 2020-07-09 | 2022-01-18 | 주식회사유한양행 | 다이아미노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 및 이의 제조방법 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4962115A (en) | 1981-10-01 | 1990-10-09 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| US4870074A (en) | 1986-04-30 | 1989-09-26 | Dainippon Pharmaceutical Co., Ltd. | Substituted benzamide derivatives, for enhancing gastrointestinal motility |
| GB9005014D0 (en) | 1990-03-06 | 1990-05-02 | Janssen Pharmaceutica Nv | N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives |
| HUT64023A (en) | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
| RU2153494C2 (ru) * | 1993-10-12 | 2000-07-27 | Дзе Дюпон Мерк Фармасьютикал Компани | 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция |
| PL313973A1 (en) * | 1993-10-12 | 1996-08-05 | Du Pont Merck Pharma | 1 n-alkyl-n-arylopyrimidin amines and their derivatives |
| IL112024A (en) | 1993-12-21 | 1999-07-14 | Novo Nordisk As | Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders |
| AU688087B2 (en) * | 1994-08-13 | 1998-03-05 | Yuhan Corporation | Novel pyrimidine derivatives and processes for the preparation thereof |
| US5739151A (en) * | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
| IN188411B (es) * | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
| US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| ES2320772T3 (es) | 2003-07-25 | 2009-05-28 | Ciba Holding Inc. | Uso de 2,4-bis (alquilamino)pirimidinas sustituidas o quinazolinas como agentes antimicrobianos. |
| AU2004268641A1 (en) * | 2003-08-29 | 2005-03-10 | Dynogen Pharmaceuticals, Inc. | Compositions useful for treating gastrointestinal motility disorders |
| US20060057972A1 (en) | 2004-09-14 | 2006-03-16 | Wikel Harold L | Adapter for a modular wireless communication device |
| US20060128726A1 (en) * | 2004-11-24 | 2006-06-15 | Xuebao Wang | Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations |
| US8816090B2 (en) | 2005-02-25 | 2014-08-26 | Pfizer Inc. | Benzisoxazole derivatives |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| WO2007062417A1 (en) * | 2005-11-28 | 2007-05-31 | Kalypsys, Inc. | Methods of preparing 2-imidazol-1-yl-4-methyl-6-pyrrolidin-2-yl-pyrimidine and 4-(1-alkylpyrrolidin-2-yl)-2-(1h-imidazol-1-yl)-6-methylpyrimidine derivatives |
| WO2007114323A1 (ja) * | 2006-04-04 | 2007-10-11 | Taisho Pharmaceutical Co., Ltd. | アミノピロリジン化合物 |
| CA2648170A1 (en) | 2006-04-10 | 2007-10-18 | Boehringer Ingelheim International Gmbh | 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer |
| WO2008114378A1 (ja) * | 2007-03-19 | 2008-09-25 | Fujitsu Limited | データ処理装置、そのデータ監視方法、そのデータ監視プログラム、及びそのデータ監視プログラムを格納した記録媒体 |
| CA2713716A1 (en) * | 2008-02-22 | 2009-08-27 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| WO2010129053A2 (en) * | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
| AU2012221927B2 (en) * | 2011-02-25 | 2016-04-28 | Yuhan Corporation | Diaminopyrimidine derivatives and processes for the preparation thereof |
-
2012
- 2012-02-24 AU AU2012221927A patent/AU2012221927B2/en active Active
- 2012-02-24 US US14/001,475 patent/US9850227B2/en active Active
- 2012-02-24 BR BR112013020641-1A patent/BR112013020641B1/pt active IP Right Grant
- 2012-02-24 PL PL12749916.8T patent/PL2678331T3/pl unknown
- 2012-02-24 ES ES12750114.6T patent/ES2587304T3/es active Active
- 2012-02-24 CA CA2827072A patent/CA2827072C/en active Active
- 2012-02-24 HU HUE12750114A patent/HUE029988T2/en unknown
- 2012-02-24 CN CN201280010406.7A patent/CN103402997B/zh active Active
- 2012-02-24 KR KR1020120018933A patent/KR101671348B1/ko active IP Right Grant
- 2012-02-24 PT PT127501146T patent/PT2678332T/pt unknown
- 2012-02-24 US US14/001,489 patent/US9890138B2/en active Active
- 2012-02-24 BR BR112013019942-3A patent/BR112013019942B1/pt active IP Right Grant
- 2012-02-24 WO PCT/KR2012/001427 patent/WO2012115480A2/en active Application Filing
- 2012-02-24 KR KR1020120018926A patent/KR101671341B1/ko active IP Right Grant
- 2012-02-24 DK DK12750114.6T patent/DK2678332T3/en active
- 2012-02-24 WO PCT/KR2012/001423 patent/WO2012115478A2/en active Application Filing
- 2012-02-24 AU AU2012221925A patent/AU2012221925B2/en active Active
- 2012-02-24 JP JP2013555368A patent/JP5980236B2/ja active Active
- 2012-02-24 RU RU2013142187/04A patent/RU2587493C2/ru active
- 2012-02-24 CN CN201280010354.3A patent/CN103391935B/zh active Active
- 2012-02-24 IN IN1519MUN2013 patent/IN2013MN01519A/en unknown
- 2012-02-24 EP EP12749916.8A patent/EP2678331B1/en active Active
- 2012-02-24 CA CA2827030A patent/CA2827030C/en active Active
- 2012-02-24 EP EP12750114.6A patent/EP2678332B1/en active Active
- 2012-02-24 PL PL12750114.6T patent/PL2678332T3/pl unknown
- 2012-02-24 JP JP2013555369A patent/JP5890436B2/ja active Active
- 2012-02-24 ES ES12749916.8T patent/ES2579830T3/es active Active
- 2012-02-24 MX MX2013009627A patent/MX336155B/es unknown
- 2012-02-24 MX MX2013009549A patent/MX337477B/es active IP Right Grant
-
2014
- 2014-02-12 HK HK14101293.6A patent/HK1188215A1/xx unknown
- 2014-02-12 HK HK14101278.5A patent/HK1188214A1/zh unknown
-
2017
- 2017-11-15 US US15/813,741 patent/US10640490B2/en active Active
- 2017-12-20 US US15/848,760 patent/US10227330B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2013MN01519A (es) | ||
| WO2012115479A3 (en) | Diaminopyrimidine derivatives and processes for the preparation thereof | |
| UA114710C2 (uk) | Похідне оксинтомодуліну та фармацевтична композиція для запобігання або лікування ожиріння, яка його містить | |
| CN112074519A8 (zh) | 作为rip1激酶抑制剂用于治疗e.g.肠易激综合征（ibs）的n-[4-氧代-2,3-二氢-1,5-苯并氧氮杂䓬-3-基]-5,6-二氢-4h-吡咯并[1,2-b]吡唑-2-甲酰胺衍生物和有关化合物 | |
| EA201270467A1 (ru) | Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты | |
| IL214572A (en) | Annals of 9 - Alkylaryl - 9h - Furin - 6 - Converted Illamine, a Pharmaceutical Composition Containing Them and These Compounds That Are a Toll-like Colton Antagonist for the Treatment of Disease | |
| WO2006104826A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
| WO2007136577A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
| EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
| TNSN07313A1 (en) | Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses | |
| DK1695710T3 (da) | Krystallinsk betad-form af ivabradinhydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne | |
| HK1120442A1 (en) | Novel opioid antagonists | |
| CL2007003266A1 (es) | Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas. | |
| EP4268814A3 (en) | Pharmaceutical composition for the treatment of dry eye | |
| MX340234B (es) | Tratamiento para transtornos gastrointestinales. | |
| MX347354B (es) | Tratamientos para trastornos gastrointestinales. | |
| IL195514A (en) | Converted Pyridyl Compounds | |
| UA100877C2 (ru) | Замещенные спироциклические производные пиперидина как лиганды рецепторов гистамина-3 (h3) | |
| CL2011000061A1 (es) | Compuestos derivados de tetrahidrocinolinas, inhibidores de la 11-beta-hsd1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes, obesidad, trastornos de ingestion de comida o dislipidemia. | |
| WO2011045232A3 (en) | Neuropeptide-2 receptor (y-2r) agonists | |
| WO2014016754A3 (en) | Pharmaceutical compositions of proton pump inhibitor | |
| EA201171271A1 (ru) | Фармацевтическая композиция в форме частиц с опиоидом и антагонистом опиоида | |
| MX2013006768A (es) | Moduladores de receptor de glucagon. | |
| EP2238105A4 (en) | NOVEL COMPOUNDS, ISOMERS, OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF, CONTAINING VANILLOID RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS THEREWITH | |
| PT1861360E (pt) | Derivados de pirrolidina como antagonistas de receptores h3 de histamina |